北大早已不是公司实控人 北大医药拟启动更名工作

Core Viewpoint - The company, Peking University Pharmaceutical Co., Ltd., is undergoing significant changes, including a shift in its actual controller and plans to rename itself and its subsidiaries to reflect this change, moving away from its association with Peking University [1] Group 1: Corporate Changes - The company announced the initiation of name changes for itself and its subsidiaries due to a change in actual control, with Xu Xiren now being the actual controller [1] - The company aims to clarify its current control relationships and align with its operational and business development needs through these name changes [1] Group 2: Strategic Adjustments - To optimize resource allocation and enhance operational efficiency, the company plans to strategically adjust its existing manufacturing system and establish a manufacturing subsidiary based in its production center in Chongqing [1][2] - The manufacturing subsidiary will focus on the production segment, allowing for centralized resource allocation and improved utilization, thereby enhancing the company's competitive edge in generic drug production [2] Group 3: Operational Efficiency - The establishment of the manufacturing subsidiary will create a clear framework for operational responsibilities, management authority, and performance targets, fostering a more effective incentive mechanism [2] - This structure is expected to motivate the manufacturing team to improve production efficiency, reduce costs, and enhance product quality, ultimately creating greater value for the company [2]